0
0
Impact of GLP-1 Agonists on Fitness Industry
Recent years have witnessed a surge in the demand for GLP-1 agonists such as Ozempic, Wegovy, and Zepbound, which were initially designed to treat type-2 diabetes but have now gained approval for weight loss. Analysts from Morgan Stanley project that the global market for these drugs will reach $105 billion by 2030, a significant increase from the previous projection of $77 billion. With an estimated adoption rate of 31.5 million individuals in the United States by 2035, comprising about 9% of the nation’s population, the popularity of these medications shows no signs of slowing down.
Concerns from Food Executives
Despite the promising prospects for these weight loss drugs, concerns have been raised by food industry executives regarding the economic implications of their widespread use. Lars Fruergaard Jorgensen, the CEO of Novo Nordisk, the company behind Ozempic and Wegovy, revealed that chief executives from food companies have reached out to him for guidance due to fears surrounding the effects of these treatments.
Response from Fitness Industry
In contrast to the apprehension expressed by food executives, professionals in the gym and fitness industry are welcoming the trend of GLP-1 agonists. Personal trainers like Michael Crandall from E by Equinox at Hudson Yards see the rise in weight loss drug users as an opportunity for promoting better physical fitness. Crandall emphasizes that the transition from weight loss to improved fitness is a natural progression that benefits individuals and the fitness industry as a whole.
Changing Exercise Patterns
A survey conducted by Morgan Stanley revealed that GLP-1 users experienced a significant increase in their workout frequency, with 77% of respondents incorporating regular exercise into their routines after starting treatment. This shift towards a more active lifestyle among drug users indicates a positive trend towards overall health improvement.
Gyms Embrace GLP-1 Users
Gyms such as Equinox, Life Time Fitness, and Xponential Fitness have recognized the growing population of GLP-1 users and are tailoring programs to cater to this demographic. Equinox has taken steps to educate its coaches on effective training methods for individuals on weight loss medications, ensuring a holistic approach to fitness. On the other hand, Life Time Fitness introduced the MIORA Longevity and Performance program, offering personalized health recommendations including exercise guidance and prescriptions for GLP-1 agonists. Xponential Fitness acquired weight loss clinic chain Lindora, further extending its reach to individuals seeking support in their weight loss journey.
Navigating Muscle Loss Concerns
One of the potential side effects of GLP-1 agonists is muscle loss, as users tend to consume less food due to reduced cravings. To address this issue, Equinox and other fitness establishments are focusing on incorporating adequate protein intake and exercise routines specifically tailored for individuals on these medications. By promoting a balanced approach to nutrition and physical activity, gyms aim to mitigate the risk of muscle loss associated with weight loss drugs.
Image/Photo credit: source url
